



Kaleido Biosciences to Participate in the JMP Securities Life Sciences Conference

June 10, 2021

LEXINGTON, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that CEO Dan Menichella will deliver a corporate presentation at the JMP Securities Life Sciences Conference at 4PM ET on Thursday, June 17.

The webcast of the presentation will be made available in the Investors & Media section of Kaleido's website at <https://investors.kaleido.com/events-presentations>. An archived replay will be available for 90 days following the event.

About Kaleido Biosciences

Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health. The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the gut's existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit <https://kaleido.com/>.

Contacts:

Kaleido Biosciences

William Duke, Jr.
Chief Financial Officer
617-890-5772
william.duke@kaleido.com

Investors

Mike Biega
Solebury Trout
617-221-9660
mbiega@soleburytrout.com

Media

Amy Bonanno
Solebury Trout
914-450-0349
abonanno@soleburytrout.com